MedTrace Logo

Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)

NCT03678818 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-05-07

No results posted yet for this study

Summary

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

Conditions

Interventions

OTHER

Medium Supplemented with Latrunculin A

A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate

Sponsors & Collaborators

  • Ibn Sina Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2019-04-20
Completion
2019-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03678818 on ClinicalTrials.gov